Asmac

Quick links to important sections

Asmac

Method of action: Bronchodilator, Tocolytic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asmac

What is Asmac? Defining the Fenoterol Entity

Property Description
Active Ingredient Fenoterol Hydrobromide
Form Solution for nebulization, Metered-dose inhaler (MDI)
Pharmacological Class Selective beta2-Adrenergic Receptor Agonist (SABA)
Common Use Relief of acute airway tightening (bronchospasm)
Origin Synthetic organic compound

Asmac is a medicinal preparation whose active substance is Fenoterol Hydrobromide, a synthetic compound that is clinically recognized for its rapid bronchodilatory effects. This drug belongs to the class of Selective beta2-Adrenergic Receptor Agonists (SABA), which ensures the medication targets the primary receptors responsible for widening the airways. Its general purpose is the swift relief of acute airway muscle constriction, known as bronchospasm, thereby increasing the capacity for airflow into the lungs. This pharmacological function as a short-acting bronchodilator makes it a crucial agent for quick intervention during sudden episodes of compromised breathing, such as those associated with obstructive airway conditions.


Pharmacological Class and Chemical Origin

Fenoterol is chemically identified as a synthetic organic compound, specifically a phenethylamine derivative and a resorcinol derivative. Under the Anatomical Therapeutic Chemical (ATC) classification, Fenoterol is grouped under R03AC, highlighting its defined role as an inhaled selective beta2-adrenoreceptor agonist. The active ingredient is commonly supplied as a racemic mixture containing both the (R,R)- and (S,S)-enantiomers, a specific characteristic of this compound. Depending on the specific product, it can be formulated either as a single product containing only Fenoterol Hydrobromide or as a combination product with other respiratory medicines.


Form and Delivery Type of Fenoterol

Fenoterol's most efficient and common route of administration for respiratory use is inhalation, as this method delivers the medication directly to the target beta2-receptors in the bronchial muscle. The medication is thus manufactured in common dosage forms optimized for this route, primarily as a solution for nebulization or as an aerosol contained within a metered-dose inhaler (MDI). The presentation as a nebulization solution is a differentiating factor, allowing administration through specialized equipment. Inhalation facilitates a rapid therapeutic effect by utilizing delivery vehicles such as an aqueous solution or propellants, ensuring high local concentration at the site of action while minimizing systemic exposure.

What side effects are possible with Asmac?

Possible Side Effects and Safety Information for Asmac

The safety profile for this medicine is systematically documented by government regulatory bodies, classifying reported effects based on the affected body system and frequency of occurrence. This structured regulatory approach helps define the risk spectrum for patients.

Adverse reactions are primarily grouped by System-Organ-Class (SOC), such as Gastrointestinal Disorders, Nervous System Disorders, and Immune System Disorders. These classifications capture the range of effects observed in clinical studies and post-marketing surveillance.

Frequency-Classified Adverse Reactions

The frequency of adverse reactions is determined using the standard regulatory framework (e.g., Very Common, Common, Uncommon, Rare, Very Rare, or Not Known). Examples of frequently documented effects generally involve the gastrointestinal system or central nervous system, but the specific list must be consulted in the official prescribing information from authorities like the FDA or EMA.

Serious Adverse Reactions and Safety Considerations

The official label explicitly identifies Serious Adverse Reactions that are deemed clinically significant, which may include events like severe hypersensitivity reactions or specific organ toxicity, requiring immediate medical attention if they occur. The regulatory basis for this drug includes specific safety-related restrictions or limitations and cautions for use. These may detail conditions where the medicine should be used with particular care or is contraindicated entirely, such as in patients with certain pre-existing organ impairments (e.g., severe hepatic or renal disease).

Population-Specific Safety Considerations are detailed when necessary, advising on differences in risk or required monitoring for groups such as the elderly or individuals with specific underlying health conditions. Furthermore, the label may contain dose- or exposure-related patterns, indicating if the likelihood of certain reactions changes during the initial phase of treatment or with prolonged use.

Overdose and Emergency Response

The official regulatory information for Asmac (Fenoterol Hydrobromide) defines overdose as an exaggeration of the drug's intended pharmacological effects, which can lead to severe clinical manifestations. The most common documented signs stem from excessive beta-adrenergic stimulation.

Documented Overdose Manifestations

Classification Official Manifestations (as labeled)
Cardiovascular Tachycardia (rapid heart rate), Palpitations, Arrhythmias, Hypertension or Hypotension, and Anginal pain.
Systemic/Metabolic Hypokalaemia (low serum potassium), Metabolic acidosis, Tremor, Headache, Nervousness, and Dizziness.

Overdosage carries the potential for life-threatening outcomes, including cardiac arrest. The official management guidelines require the immediate discontinuation of the drug and the institution of appropriate medical and supportive therapy. In certain circumstances, the judicious use of a cardiovascular beta-receptor blocker may be indicated to counteract the effects, though this must be strictly monitored due to the risk of precipitating severe bronchospasm.

When Immediate Medical Help is Required

Seek immediate emergency help or contact a poison control center/emergency room immediately if an overdose is suspected or if serious symptoms, such as a fast or irregular heartbeat, are noticed.

Therapeutic Uses of Asmac

The medication is commonly used to help with symptomatic relief across key therapeutic domains, which may assist with managing conditions that involve periods of heightened symptoms. The therapeutic benefit contributes to easing the overall symptom load during acute episodes. This medication is applied across domains where additional symptomatic support is needed, similar to products in a related therapeutic category used for symptomatic management.


Easing Acute and Pronounced Symptom Intensity

This medication is relevant for managing symptom clusters that may become intense or disruptive, and is commonly used during phases when symptoms become more noticeable. It is applicable within clinical settings that involve acute or unstable symptom patterns, and supports general well-being during symptomatic phases. The symptomatic support is relevant for addressing symptoms related to physical discomfort, systemic imbalance, and symptoms that create noticeable physiological strain.

“The supportive therapeutic approach assists patients with managing symptom fluctuations during acute phases.”


Supportive Relief for Functional Stability

Asmac is commonly used across conditions presenting with acute episodes and conditions where functional stability may become affected. By managing symptoms that interfere with daily comfort, Asmac contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities. It is relevant in contexts involving heightened systemic burden and often used during phases when symptoms become more noticeable.

Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Eligibility to Use Asmac (Fenoterol)

The criteria for using Asmac are strictly defined by official regulatory bodies based on specific patient populations and pre-existing medical conditions.


Eligibility Scope

Category Regulatory Status
Populations Contraindicated Must Not Use: Patients with known hypersensitivity to Fenoterol, tachyarrhythmia, or hypertrophic obstructive cardiomyopathy (HOCM) [Source 1.6, 2.6].
Conditional Use/Caution Risk Assessment Required: Patients with severe cardiovascular disorders (e.g., coronary insufficiency, hypertension), diabetes mellitus, hyperthyroidism, or conditions like narrow-angle glaucoma [Source 1.1, 1.2].
Age Limitations Not Recommended: Use is generally not recommended in children under 4 years of age; use in older children and adults is established [Source 2.6].
Pregnancy/Lactation Conditional/Restricted: Use during the first trimester and near-term is restricted. Caution is advised during lactation as Fenoterol is excreted into breast milk [Source 1.1].

Official Eligibility Statements

Official regulatory documents define non-eligibility primarily through absolute contraindications related to cardiac stability, which strictly prohibit use in certain heart conditions. Eligibility is further constrained by conditional use statements that mandate caution for patients with coexisting metabolic and cardiovascular disorders. Finally, regulatory rules place limitations on age groups and physiological states such as pregnancy and lactation [Source 1.6, 2.6].

What should I know about interactions with other medicines?

The regulatory interaction profile for Fenoterol (Asmac), a beta2-adrenergic agonist, is strictly defined by pharmacodynamic interactions documented in official government labeling. The profile establishes constraints based on antagonism of therapeutic effect and augmentation of systemic side effects, such as cardiovascular stimulation and hypokalaemia.


Category Official Regulatory Information
Interaction-related restrictions Co-administration with Non-cardioselective beta-blockers is strictly restricted due to the documented risk of a potentially serious reduction in bronchodilation (antagonism).
Medicinal product categories with documented interactions Other beta-adrenergics (sympathomimetic agents), Anticholinergics, Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), Xanthine Derivatives, Corticosteroids, Diuretics, and Halogenated Hydrocarbon Anaesthetics.
Mechanistic basis of interactions Pharmacodynamic Reinforcement/Additive Effects (increasing cardiovascular effects or hypokalaemia risk).
Population-specific interaction notes Cautions are noted for patients receiving Digitalis/Digoxin and patients with severe airway obstruction when co-administered with Xanthine derivatives, corticosteroids, or diuretics due to amplified hypokalaemia risk.

Official interaction statements: Non-cardioselective beta-blockers are contraindicated. Co-administration with MAOIs or TCAs may potentiate vascular effects. Concomitant use of Xanthine derivatives, Corticosteroids, or Diuretics may increase the risk of hypokalaemia. Halogenated Hydrocarbon Anaesthetics may increase cardiovascular susceptibility.

Connection to the overall interaction profile: Official labeling establishes clear restrictions and lists specific drug classes that reinforce certain physiological effects, defining constraints based on additive risks. The documented interaction structure is focused on the beta2-adrenergic agonist activity and associated systemic effects. (193 words)

Mechanism of Action

Sympathetic Receptor Targeting and Airway Relaxation

Fenoterol acts as a selective agonist at the beta2-Adrenergic Receptors (beta2-AR), which are predominantly located on the smooth muscle cells of the airways. By binding to these receptors, the drug initiates an intracellular signaling cascade that modulates the target pathway, consistent with beta2-AR activation. This mechanism involves the targeted activation of the beta2-AR signaling cascade, resulting in the modulation of muscle tone within the bronchial smooth muscle.


The Intracellular cAMP Relaxation Cascade

The activation of the beta2-AR stimulates the Gs-protein, leading to the increase of the second messenger cyclic AMP (cAMP) within the cell. The subsequent activation of Protein Kinase A (PKA) modifies proteins that control intracellular calcium ion ( Ca^2+) levels and inhibits the enzyme responsible for initiating smooth muscle contraction (MLCK). This molecular cascade results in the relaxation of the tracheobronchial smooth muscle and the physiological increase in airway diameter (bronchodilation).


Mechanistic Constraints

The drug’s action is focused on modulating muscle tone via the beta2-AR pathway, but this mechanism is subject to constraints, such as receptor desensitization (tachyphylaxis), reflecting reduced cellular response under sustained stimulation. This reduction in beta2-AR sensitivity represents a physiological limitation characterized by the diminishment of the maximum obtainable cellular response.

Dosage and Administration Information

How to use Asmac — Official Administration Guidelines

Asmac (Fenoterol Hydrobromide) is administered exclusively by inhalation, utilizing either a metered-dose inhaler (MDI) or a solution for nebulization. The official instructions define specific dosing and timing constraints for the proper administration of this medicine.

Dosing and Frequency

For acute relief, the standard regimen involves inhaling one actuation (100 mug) of the MDI. Should adequate relief not be achieved, a second actuation may be taken after a mandatory 5 minute interval. The established protocol dictates that an acute episode should not require more than two initial actuations before professional medical help must be sought. For intermittent use, the standard administration is one to two actuations. The total daily usage is restricted to a maximum of eight actuations in a 24 hour period.

Administration Conditions

The nebulizer solution requires dilution with physiological saline (0.9% NaCl) to a total volume of 3 to 4 mL before being administered. The MDI device requires a priming procedure before its initial use or after a period of non-use. Following inhalation, patients are required to gargle with water.

Specific rules apply to pediatric use: children over 6 years may follow the adult regimen but only under adult supervision, while younger children require strict medical supervision for weight-based dosing. The official use is structured around an as-needed basis for acute intervention, with the daily maximum constraint defining the limit of self-administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Asmac (Fenoterol)


Evidence for Use in Acute Airway Tightening (Bronchospasm)

The evidence base for Fenoterol's primary research focus relates to studies during episodes of sudden airway constriction, often related to conditions where symptoms may vary in intensity. Research has explored the medicine’s action primarily through short-term, randomized controlled trials (RCTs). These studies typically involved populations of adults and children experiencing acute episodes, and they aimed to measure specific airflow parameters after a single dose or a brief treatment course.

Researchers specifically monitored lung function measures, such as Forced Expiratory Volume in 1 second ( FEV1) and Peak Expiratory Flow (PEF), to track changes in airflow and the time to reach peak measured response. Studies reported patterns in the measured outcomes observed during these short intervals, often lasting only a few hours. However, the existing research primarily contributes to understanding short-term changes only. Evidence remains limited regarding the long-term impact on the disease progression itself.

Studies Evaluating Fenoterol in Special Populations

Research has explored studies of Fenoterol in various special populations, including children with acute bronchial obstruction. Another distinct area explored Fenoterol's study in pregnant women for tocolysis, a medical scenario where the aim is to inhibit uterine contractions. These studies, which typically involved intravenous administration, monitored outcomes related to maternal and fetal heart rate and tracked the process outcome of delaying delivery over defined time intervals. Research for this group has explored short-term symptom changes, but data are still emerging and certainty remains low regarding its overall effect on long-term neonatal health outcomes.

Evidence Consistency and Remaining Research Gaps

Overall, the evidence base for studies of Fenoterol in acute airway constriction is classified as High for short-term physiological parameters measured, based on the consistency of findings in numerous comparative and randomized controlled studies. The research describes how symptoms are measured and reports patterns related to functional outcomes over brief intervals. However, there are still research gaps: data for subgroup findings are uncertain, particularly for patients with certain comorbidities. Furthermore, there is limited information for long-term outcomes or durability of effect, especially when studied regularly for chronic conditions.

Frequently Asked Questions (FAQ)

Common questions about Asmac (FAQ)


Q: How quickly does Asmac start to work after I use it?

A: Studies and official information indicate that Fenoterol (Asmac) is designed for a rapid onset of action. The initial effect of the medicine after inhalation is typically observed within 1 to 5 minutes, providing quick relief for sudden airway tightening.


Q: Is a headache a common side effect of Asmac?

A: According to official frequency classifications in the product documentation, headache is documented as a common adverse reaction associated with Fenoterol use. Regulatory documents indicate that if side effects, such as a headache, are bothersome or persist, individuals may need to consult with a healthcare provider.


Q: Why do people sometimes say Asmac makes them feel jittery?

A: Official regulatory documents acknowledge that effects like tremor (shaking) and feelings of nervousness or restlessness are common side effects of this type of medicine. These effects are related to the drug's activity on the body's nervous system and may be described by users as feeling 'jittery.'


Q: Is Asmac safe for use during pregnancy, according to official sources?

A: Official regulatory documents specifically state that use of Fenoterol during the first trimester of pregnancy and near-term is restricted. Official documentation restricts use unless the potential benefit is determined to outweigh the potential risk, as assessed by a healthcare professional.


Q: What are the official guidelines for using Asmac while breastfeeding?

A: Regulatory information advises caution during lactation because official data confirms that Fenoterol is excreted into breast milk. The regulatory basis for caution requires that the mother’s clinical necessity for the drug be weighed against the potential effects on the infant.


Q: Can Asmac be used to prevent breathing issues before exercise?

A: Fenoterol's primary approved use, as outlined in regulatory documents, is for the relief of acute symptoms of airway tightening, known as bronchospasm. Its use is focused on intervening during a sudden episode rather than providing long-term prevention.


Q: What should I do if the side effects of Asmac bother me?

A: The official Patient Information Leaflet notes that individuals experiencing bothersome or persistent side effects should consult a healthcare provider. This is to ensure that any side effects are addressed appropriately based on individual circumstances.


Q: What is the difference in safety classification of Asmac compared to other similar drugs?

A: Fenoterol is officially classified as a Short-Acting beta2-Adrenergic Receptor Agonist (SABA), defining its function in widening the airways. Its regulatory safety classification for pregnancy is defined within official documents of relevant health authorities.


Q: Is Asmac the same type of medicine as [similar common drug name]?

A: Fenoterol (Asmac) is classified as a beta2-adrenergic agonist. While other medications may belong to the same broader class of bronchodilators, the unique active substance in Asmac, as defined in official documentation, is specifically Fenoterol Hydrobromide.


Q: Can Asmac affect sleep or cause insomnia?

A: Yes, regulatory adverse reaction documents list insomnia (difficulty sleeping) as a possible side effect. Insomnia is typically classified as a less common or uncommon reaction associated with the use of Fenoterol.


Q: What happens if I forget to use Asmac at the scheduled time?

A: Official administration instructions specify that Asmac is generally intended for use on an as-needed basis for acute relief of symptoms. This means it is not typically part of a fixed, scheduled, regular maintenance plan.


Q: Is it possible to be allergic to Asmac?

A: Yes, official regulatory documents explicitly state that known hypersensitivity to Fenoterol Hydrobromide or any of the product’s listed ingredients is a contraindication. This means that having a known allergy is an official reason why the drug must not be used.


Q: What is the risk of long-term use of Asmac?

A: Regulatory safety warnings related to this class of medication note that frequent or excessive use may be associated with increased risks, including a potential worsening of airway symptoms over time. The product labeling defines maximum daily usage constraints, which are important to respect to help minimize risk.


Q: Does Asmac show up on drug tests?

A: Fenoterol is classified as a beta2-agonist. These substances are generally included in the monitoring programs of global sports regulatory bodies (such as WADA) and may be detected in specific tests designed for performance-enhancing drugs.


Q: Are there any known interactions between Asmac and supplements like Vitamin D or C?

A: Regulatory interaction documents primarily focus on drug-drug interactions, listing specific categories of prescription medicines. Official prescribing information typically does not include detailed information on interactions with specific vitamins or most dietary supplements.


Q: What does 'contraindication' mean regarding Asmac?

A: A contraindication is an official statement in regulatory documents that describes a pre-existing medical condition, such as certain heart issues or a known allergy, where the medicine must not be used. This is because using the drug under these circumstances is considered to carry an unacceptably high risk.


Q: Where can I find the official regulatory information (like FDA or EMA documents) on Asmac?

A: Official regulatory documents, such as the Prescribing Information (US) or Summary of Product Characteristics (EU), can be accessed through public, government-run medical databases. Examples include the NIH DailyMed website or the European Medicines Agency (EMA) public website.


Q: What is the estimated time for the full effect of Asmac to be noticed?

A: The full (or peak) effect of Fenoterol after inhalation, which reflects the maximum widening of the airways, is generally reported in clinical studies to occur approximately 30 minutes following administration.


Q: Can older adults use Asmac without major changes to their treatment plan?

A: Official documentation advises caution for use in the elderly population. This caution indicates that adjustments to the treatment approach or closer monitoring of specific systemic side effects, such as cardiovascular effects, may be necessary.


Q: Why is my breathing still not perfect even though I'm using Asmac?

A: The regulatory purpose of Asmac is for the rapid relief of acute symptoms of airway tightening. It is not defined as a treatment that provides a complete cure or long-term control over the underlying chronic condition. Complete relief of symptoms is not guaranteed by the official indications.


Q: Does Asmac change how the immune system works?

A: Official adverse reaction documents include Immune System Disorders as a general category for adverse events. However, specific, detailed regulatory claims about the drug's overall effect on immune system function or suppression are typically not provided.


Q: Do official documents mention anything about Asmac affecting vision?

A: Official adverse reaction lists do include visual disturbances, such as blurred vision, as a possible side effect. This is typically classified as a rare or uncommon effect.


Q: Can Asmac cause changes in mood or anxiety?

A: Yes, regulatory documentation classifies side effects that involve the nervous system, including feelings of nervousness or restlessness. These effects may be associated with or contribute to changes in mood or anxiety levels.


Q: What is the purpose of the filler ingredients in the Asmac product?

A: Official product documentation lists 'Excipients' (filler ingredients) that are included for non-therapeutic purposes. These ingredients ensure the product’s correct volume, consistency, stability, and proper delivery of the active drug, Fenoterol.


Q: Can Asmac be taken with over-the-counter pain relievers like ibuprofen?

A: Official interaction documents list specific medicinal product categories. Interactions between Fenoterol and common non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen are not routinely listed. However, concurrent use of some NSAIDs with beta2-agonists is sometimes associated with an increased risk of high blood pressure.

How should Asmac be stored and disposed of?

Storage Requirements

Asmac (Fenoterol Hydrobromide) must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and protected from excessive heat, moisture, and light. The nebulization solution must not be frozen. Metered-dose inhaler (MDI) canisters are pressurized and must not be exposed to temperatures above 50 C or punctured. All medication must be kept securely out of the reach of children.

Stability and Container Rules

For the nebulization solution, single-use vials must be discarded immediately after one use. Opened multi-dose bottles are stable for up to 30 days at room temperature. The product must be stored in its original, tightly closed container.

Disposal Instructions

Disposal must follow local regulations for pharmaceutical waste. The preferred method for unused or expired product is a community drug take-back program. Medicines should not be flushed down the sink or toilet unless explicitly labeled for that disposal. If a take-back program is unavailable, mix the medicine with an undesirable substance, seal it in a bag, and place it in the household trash, ensuring all identifying information is removed from the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asmac found in:

A-Z Index: